Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery

E. Santagostino, P. M. Mannucci, A. Gringeri, G. Tagariello, F. Baudo, K. A. Bauer, R. D. Rosenberg

Research output: Contribution to journalArticle

Abstract

Purer factor IX (FIX) concentrates have been produced for the treatment of hemophilia B in the attempt to reduce the risk of thrombotic complications associated with the use of prothrombin complex concentrates. To evaluate ex vivo whether or not FIX concentrates activate the coagulation system in conditions associated with a high risk for thrombosis, we measured markers of hypercoagulability in 10 patients with hemophilia B who underwent surgery, mainly orthopedic procedures, covered by multiple concentrate infusions (40-80 U/kg/day). Post-infusion plasma levels of prothrombin fragment 1+2 and factor X activation peptide did not differ significantly from the presurgical levels, neither before nor after each concentrate dose. Therefore, it appears that prolonged treatment of patients with hemophilia B undergoing high risk surgical procedures with high doses of FIX concentrate does not cause systemic activation of coagulation. This suggests that purified FIX concentrates are preferable to prothrombin complex concentrates for conditions associated with an increased risk of thrombosis.

Original languageEnglish
Pages (from-to)737-740
Number of pages4
JournalThrombosis and Haemostasis
Volume71
Issue number6
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery'. Together they form a unique fingerprint.

  • Cite this